FEIBA is effective across many types and severities of bleeds in a variety of clinical settings

In two prospective studies, FEIBA was shown to stop bleeds quickly.1,2

Two recent, prospective, randomised clinical studies demonstrated the merits of FEIBA as an efficacious prophylaxis therapy for the prevention of bleeding episodes.16

Demonstrated efficacy in multiple clinical settings

  • During ITI: FEIBA haemophilic can be used to prevent bleeding during ITI and avoid haemophilic arthropathy5,7,8
  • In surgery: FEIBA provides haemostatic control in patients undergoing both major and minor surgical procedures4,9-12
  • For patients with acquired haemophilia: Multiple studies support the demonstrated efficacy of FEIBA in patients with acquired haemophilia13-15


  1. 1. Hilgartner MW, Knatterud GL. The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in haemophiliacs with inhibitors. Blood. 1983:61:36-40.
  2. 2. Astermark J, Donfield SM, DiMichele DM, Gringeri A, Gilbert SA, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood. 2007;109(2):546-551.
  3. 3. Leissinger CA, Becton DL, Ewing NP, Valentino LA. Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors. Haemophilia. 2007:1-7.
  4. 4. DiMichele D, Négrier C. A retrospective postlicensure survey of FEIBA efficacy and safety. Haemophilia. 2006;12:352-362.
  5. 5. Valentino LA. The benefits of prophylactic treatment with APCC in patients with haemophilia and high-titre inhibitors: a retrospective case series. Haemophilia. 2009: 15:733-742.
  6. 6. Ettingshausen CE, Kreuz W. Early long-term FEIBA prophylaxis in haemophilia A patients with inhibitor after failing immune tolerance induction: A prospective clinical case series. Haemophilia: 2010: 16:90-100.
  7. 7. Kreuz W, Escuriola-Ettinghausen C, Mentzer D, Martinez I, Becker S, Stoll H, et al. Factor VIII inhibitor bypass activity (FEIBA) for prophylaxis during immune tolerance induction (ITI) in patients with high-responding inhibitors. Blood 96 (11)266a. Presented at ASH, 42nd Annual Meeting Dec. 1-5, 2000 San Francisco, CA
  8. 8. Leissinger CA. Prophylaxis in haemophilia patients with inhibitors. Haemophilia. 2006; 12 (Suppl 6):67-72
  9. 9. Lauroua P, Ferrer AM, Guerin V. Successful major and minor surgery using factor VIII inhibitor bypassing activity in patients with haemophilia A and inhibitors. Haemophilia. 2009:15:1300-1307.
  10. 10. Négrier C, Pousse M, Fleury R, et al. Surgical interventions with FEIBA (SURF)—Studying the feasibility of surgery in inhibitor patients. Poster presented at the International Society on Thrombosis and Haemostasis Congress, 2009.
  11. 11. Négrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P., et al. Multicenter Retrospective Study on the Utilization of FEIBA in France in Patients with Factor VIII and Factor IX Inhibitors. Thromb Haemost. 1997:77:1113-1119.
  12. 12. Tjønnfjord GE. Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX: the updated Norwegian experience. Haemophilia. 2004:10(Suppl. 2):41-45.
  13. 13. Sallah S. Treatment of acquired haemophilia with factor eight inhibitor bypassing activity. Haemophilia. 2004:10:169-173.
  14. 14. Goudemand J. Treatment of bleeding episodes occurring in patients with acquired haemophilia with FEIBA: the French experience. Haemophilia: 2004:10(Suppl 3),68-72: abstract 14 PO 14.
  15. 15. Holme PA, Brosstad F, Tjønnfjord GE. Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies. Haemophilia. 2005:11:510-515.
  16. 16. Antunes SV, Tangada S, Stasyshyn O, et al. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors [published online ahead of print August 1, 2013]. Haemophilia. 2014;20(1):65-72. DOI:10.1111/hae.12246.

Treatment challenges

Identify challenges in treating inhibitors and understand how to address them. Read more


Learn more about the compelling recent research on FEIBA prophylaxis. Read more

Integral to inhibitor management

Learn how FEIBA is integral to the management of patients with inhibitors. Read more